Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19
are they worth the risk?
DOI:
https://doi.org/10.5712/rbmfc16(43)2573Keywords:
Quaternary Prevention, Hydroxychloroquine, Chloroquine, Coronavirus Infections.Abstract
Quaternary prevention: action taken to recognize people or populations at risk of overmedicalization and to protect them, suggesting scientifically and ethically acceptable procedures. In 2019, a disease classified as Coronavirus-Induced-Disease, responsible for the COVID-19 pandemic, emerged in Wuhan. Lives are being cut short and the search for treatment is a global public health issue. In vitro, hydroxychloroquine and chloroquine inhibit this agent, so it was suggested that such drugs should be part of the early treatment. A review was performed in PubMed and LILACS databases and manual search of journals in The New England Journal of Medicine (NEJM) and in the Journal of the American Medical Association (JAMA), under the terms: “hydroxychloroquine, chloroquine and COVID-19”,“Hydroxychloroquine, chloroquine and COVID-19” and “chloroquine and COVID-19”. The Exclusion Criteria: duplicate articles, hydroxychloroquine and chloroquine outside the context of COVID-19, other aspects of COVID-19 and magazines sponsored by the pharmaceutical industry. 115 articles were found in the databases after applying the exclusion criteria and 6 were selected for review. Other studies on quaternary prevention were researched in order to discuss the excess of medical intervention. There is still no ideal treatment to control the virus. It is up to the health professionals, in particular, the Family Practice Doctors, the critical thinking applied to all the results presented in the studies, no matter how attractive they may seem at first sight.
Downloads
Metrics
References
(1) Mangin D, Heath I. Multimorbidity and Quaternary Prevention (P4). Rev Bras Med Fam Comunidade. 2015 [6 jun 2020];10(35):1-5. Disponível em: https://www.rbmfc.org.br/rbmfc/article/view/1069 DOI: https://doi.org/10.5712/rbmfc10(35)1069
(2) Jamoulle M. Prevenção quaternária: primeiro não causar dano. Rev Bras Med Fam Comunidade. 2015 [6 jun 2020];10(35):1-3. Disponível em: https://www.rbmfc.org.br/rbmfc/article/view/1064/697
(3) Santos CMC, Pimenta CAM, Nobre MRC. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Rev Latino-am Enfermagem. 2007 [14 jun 2020]; 15(3). Disponível em:https://www.scielo.br/pdf/rlae/v15n3/pt_v15n3a23.pd
(4) Jamoulle M. Quaternary prevention, an answer of family doctors to overmedicalization. Int J Health Policy Manag. 2015 [6 jun 2020];4(2):61-64. Disponível em: http://dx.doi.org/10.15171/ijhpm.2015.24. DOI: https://doi.org/10.15171/ijhpm.2015.24
(5) Randomised Evaluation of COVID-19 Therapy. RECOVERY [V6.0 2020-05-14]. University of Oxford. 2020: 4 [06 jun 2020]. Disponível em: https://www.recoverytrial.net/files/recovery-protocol-v6-0-2020-05-14.pdf 6. World Health Organization. [07 jun 2020]. Disponível em: https://www.who.int/health-topics/coronavirus#tab=tab_1
(6) World Health Organization. [07 jun 2020]. Disponível em: https://www.who.int/health-topics/coronavirus#tab=tab_1
(7) Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 [14 jun 2020]; 323(13): 1239-1242. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/2762130 PMID: 32091533 DOI: https://doi.org/10.1001/jama.2020.2648
(8) BMJ. BMJ Best Practice - COVID-19. 2020 [14 jun 2020]. Disponível em: https://bestpractice.bmj.com/topics/pt-br/3000168/pdf/3000168/COVID-19.pdf
(9) Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni in Medicina. 2020 [10 jun 2020]; 2:198-211. Disponível em: https://www.infezmed.it/media/journal/Vol_28_2_2020_10.pdf PMID: 32335561
(10) Touret M, Lamballerie X. Of chloroquine and COVID-19. Elsevier. 2020 [07 jun 2020]; 177:104762. Disponível em: http://doi.org/10.101016/j.antiviral.2020.104762
(11) Gross DMP, Camacho ACLF, Lage LR, Daher DV, Mota CP. Prevenção Quaternária na Gestão da Atenção Primária à Saúde: Revisão Integrativa. Rev enferm UFPE on line. 2016 [5 jun 2020]; 10(4):3608-19. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/bde-29974
(12) Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, 2019 [07 jun 2020]; 21(7):e1000097. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707599/ DOI: https://doi.org/10.1371/journal.pmed.1000097
(13) Singh S. How to Conduct and Interpret Systematic Reviews and Meta-Analyses. Journal of the American College of Gastroenterology. 2017 [14 jun 2020]; 8, e93. Disponível em:
(14) Modesto AADA. Nem tudo que reluz é ouro. Rev Bras Med Fam Comunidade. 2019 [6 jun 2020]; 14(41):1781. Disponível em: https://rbmfc.org.br/rbmfc/article/view/1781/968 DOI: https://doi.org/10.5712/rbmfc14(41)1781
(15) Matthieu M, Viet-Thi T, Mathilde R, Amélie C, Romain P, Constance G et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020 [7 jun 2020]; 369:m1844. Disponível em: https://www.bmj.com/content/bmj/369/bmj.m1844.full.pdf
(16) Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicroial Chemotherapy. 2020 [7 jun 2020]; 41(2): 145-151. Disponível em: https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa114/5810487
(17) Yao X, Ye F, Zhang M, Cui C,Huang B, Niu P et al.In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020 [07 jun 2020]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32150618/ DOI: https://doi.org/10.1093/cid/ciaa237
(18) Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19. The New England Journal of Medicine, 2020 [07 jun 2020]. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2012410 DOI: https://doi.org/10.1056/NEJMoa2012410
(19) Rosenberg ES et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020 [06 jun 2020]. Disponível em: https://jamanetwork.com/ DOI: https://doi.org/10.1001/jama.2020.8630
(20) Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 [8 jun 2020]; 369:m1849. Disponível em: https://www.bmj.com/content/369/bmj.m1849.long PMID: 32409561 DOI: https://doi.org/10.1136/bmj.m1849
(21) David R. Boulware, M.D. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19. The New England Journal of Medicine, 2020 [06 jun 2020]. Disponível em:https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
(22) Menezes CR, Sanches C, Chequer FMD. Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para o tratamento da COVID-19. O que sabemos até o momento?. J. Health Biol Sci. 2020 [14 abr 2020]; 8(1): 1-9. Disponível em: http: //doi.10.12662/2317-3206jhbs.v8i1.3206.p1-9.2020 DOI: https://doi.org/10.12662/2317-3076jhbs.v8i1.3206.p1-9.2020
(23) Cardoso RV. Prevenção quaternária: um olhar sobre a medicalização na prática dos médicos de família. Rev. Bras. Med. Fam. Comunidade. 2015 [7 jun 2020]; 10(35): 1-10. Disponível em: http://dx.doi.org/10.5712/rbmfc10(35)1117 DOI: https://doi.org/10.5712/rbmfc10(35)1117
(24) Lopes JMC, Dias LC. Princípios da medicina de família e comunidade. In: Tratado de Medicina de Família e Comunidade. Cap 1. Artmed. Porto Alegre. 2019.
(25) Gao Q, Hu Y, Dai Z, Xiao F, Wang J, Wu J. Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020 [7 jun 2020] 2(8): 113-122. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32064853/ DOI: https://doi.org/10.46234/ccdcw2020.032
(26) De Jonghe M. (2015). Prevenção quaternária como diretriz para a equipe editorial de uma revista de medicina baseada em evidência. Rev Bras Med Fam Comunidade. 2015 [7 jun 2020];10(35): 1-7. Disponível em: https://doi.org/10.5712/rbmfc10(35)1067 DOI: https://doi.org/10.5712/rbmfc10(35)1067
(27) Assistente de Pesquisa Científica, Centro Cochrane do Brasil. Sentinel reader dos comentários dos artigos do The Evidence Based Journals Group McMaster Online Rating of Evidence. Doutoranda em Medicina Interna e Terapêutica, Universidade Federal de São Paulo - Escola Paulista de Medicina (UNIFESPEPM), São Paulo, SP.J Vasc Bras 2007;6(1):1-4.
(28) Jamoulle M, Gomes LF. Prevenção Quaternária e limites em medicina. Rev Bras Med Fam Comunidade. 2014 [6 jun 2020];9(31):186-91. Disponível em: http://dx.doi.org/10.5712/rbmfc9(31)867 DOI: https://doi.org/10.5712/rbmfc9(31)867
(29) Banden LR,Rubin EJ. Covid-19 — The Search for Effective Therap. The New England Journal of Medicine. 2020 [7 jun 2020]; 382:1851-1852. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMe2005477
(30) Merhy E. Vida e Resistência Frente a COVID-19 - TV REDE UNIDA. [07 jun 2020]. Disponível em: https://www.youtube.com/watch?v=qY5GB32dOLU&t=3635s
(31) Rother ET. Revisão sistemática X revisão narrativa. Acta paul. enferm. [Internet]. 2007 June [cited 2021 Feb 04] ; 20( 2 ): v-vi. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002007000200001&lng=en. https://doi.org/10.1590/S0103-21002007000200001 DOI: https://doi.org/10.1590/S0103-21002007000200001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Alexandre José de Melo Neto, Denise Mota Araripe Pereira Fernandes, Lana Muriely Borges de Assis, Marina de Lima Pinheiro, Anne Thaísa Dantas Carvalho, Melissa Maria Medeiros de Morais
This work is licensed under a Creative Commons Attribution 4.0 International License.
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.
